| Surveillance of antimicrobial resistance in Lebanese hospitals: retrospective nationwide compiled data K Chamoun, M Farah, G Araj, Z Daoud, R Moghnieh, P Salameh, ... International journal of infectious diseases 46, 64-70, 2016 | 128 | 2016 |
| Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: a retrospective case series K Chamoun, S Choquet, E Boyle, C Houillier, D Larrieu-Ciron, A Al Jijakli, ... Neurology 88 (1), 101-102, 2017 | 69 | 2017 |
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience K Chamoun, H Kantarjian, R Atallah, GN Gonzalez, GC Issa, MB Rios, ... Journal of hematology & oncology 12, 1-10, 2019 | 32 | 2019 |
| Socioeconomic factors and survival of multiple myeloma patients K Chamoun, A Firoozmand, P Caimi, P Fu, S Cao, F Otegbeye, L Metheny, ... Cancers 13 (4), 590, 2021 | 21 | 2021 |
| Early detection of transformation to BPDCN in a patient with MDS K Chamoun, S Loghavi, N Pemmaraju, M Konopleva, M Kroll, ... Experimental hematology & oncology 7, 1-5, 2018 | 16 | 2018 |
| Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia K Chamoun, HM Kantarjian, X Wang, K Naqvi, F Aung, G Garcia‐Manero, ... Cancer 125 (18), 3219-3224, 2019 | 15 | 2019 |
| Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged≥ 75 years Q Bashir, K Chamoun, DR Milton, M Khan, S Ahmed, R Mehta, UR Popat, ... Leukemia & lymphoma 60 (14), 3536-3543, 2019 | 14 | 2019 |
| Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study M Maerevoet, JM Zijlstra, G Follows, RO Casasnovas, JSP Vermaat, ... Journal of Hematology & Oncology 14, 1-4, 2021 | 13 | 2021 |
| Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia M Khan, T Muzzafar, H Kantarjian, I Badar, N Short, X Wang, K Chamoun, ... Annals of hematology 97, 1183-1191, 2018 | 13 | 2018 |
| A phase 2 study to evaluate the efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors SK Tantravahi, SJ Kim, D Sundar, AB Patel, AD Pomicter, KM Boucher, ... Blood 138, 143, 2021 | 10 | 2021 |
| Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents S Lee, S Mohan, J Knupp, K Chamoun, A de Jonge, F Yang, E Baloglu, ... Journal of Hematology & Oncology 15 (1), 103, 2022 | 9 | 2022 |
| CPX-351 for the treatment of high-risk patients with acute myeloid leukemia R Assi, HM Kantarjian, S Verstovsek, G Garcia-Manero, M Konopleva, ... Blood 128 (22), 4047, 2016 | 8 | 2016 |
| Allogeneic transplantation after myeloablative rituximab/BEAM±bortezomib for patients with relapsed/refractory lymphoid malignancies: 5-year follow-up results K Chamoun, DR Milton, C Ledesma, KH Young, EJ Jabbour, G Alatrash, ... Biology of Blood and Marrow Transplantation 25 (7), 1347-1354, 2019 | 7 | 2019 |
| Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia K Chamoun, G Borthakur Expert opinion on investigational drugs 27 (8), 661-666, 2018 | 7 | 2018 |
| CML patients outcome after TKI discontinuation: a single institution experience in the US K Chamoun, HM Kantarjian, MB Rios, R Assi, G Garcia-Manero, ... Blood 128 (22), 1923, 2016 | 7 | 2016 |
| A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-Naïve myelofibrosis H Ali, A Kishtagari, K Maher, SR Mohan, K Ansaldo, X Wang, K Chamoun, ... Blood 140 (Supplement 1), 3986-3987, 2022 | 6 | 2022 |
| Refractory inflammatory myopathy in hematopoietic stem cell transplant patients with chronic graft-versus-host disease: report of two cases S Golec, E Rabinovich, M Cohen, L Baer, K Chamoun, M Lima Hematology, Transfusion and Cell Therapy 41, 268-271, 2019 | 6 | 2019 |
| Comparison of the effectiveness and safety of the oral selective inhibitor of nuclear export, selinexor, in diffuse large B cell lymphoma subtypes RO Casasnovas, G Follows, JM Zijlstra, JSP Vermaat, N Kalakonda, ... Clinical Lymphoma Myeloma and Leukemia 22 (1), 24-33, 2022 | 5 | 2022 |
| A case of neurocognitive deficit strongly related to dasatinib therapy K Chamoun, E Rabinovich, L Baer, P Fastenau, M Lima Hematology, Transfusion and Cell Therapy 42, 80-82, 2020 | 5 | 2020 |
| Nonbacterial thrombotic endocarditis N Parker, R Atallah, N Ojile, K Chamoun, F Nehme, M Vindhyal Kansas Journal of Medicine 13, 61, 2020 | 5 | 2020 |
